What is the pharmacologic action of ipratropium in respiratory therapy?

What is the pharmacologic action of ipratropium in respiratory therapy?

• A. Long-acting inhaled beta agonist
• B. Inhaled corticosteroid
• C. Mucolytic agent
• D. Short-acting inhaled anticholinergic to promote bronchodilation

Answer: (D)

Ipclatr opium is an inhaled anticholinergic that blocks muscarinic receptors in the airway smooth muscle. By inhibiting acetylcholine-mediated parasympathetic stimulation, it prevents bronchoconstriction and promotes bronchodilation. This explains its short-acting effect—onset in about 15–30 minutes with a duration of roughly 4–6 hours—classifying it as a short-acting inhaled anticholinergic. It does not work as an anti-inflammatory corticosteroid, nor does it act as a mucolytic to thin mucus, and it is not a beta-adrenergic agonist that directly stimulates beta receptors.

Ipclatr opium is an inhaled anticholinergic that blocks muscarinic receptors in the airway smooth muscle. By inhibiting acetylcholine-mediated parasympathetic stimulation, it prevents bronchoconstriction and promotes bronchodilation. This explains its short-acting effect—onset in about 15–30 minutes with a duration of roughly 4–6 hours—classifying it as a short-acting inhaled anticholinergic. It does not work as an anti-inflammatory corticosteroid, nor does it act as a mucolytic to thin mucus, and it is not a beta-adrenergic agonist that directly stimulates beta receptors.